The combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy for breast cancer:a meta-analysis of randomized evidence
10.3760/cma.j.issn.1673-422X.2015.04.008
- VernacularTitle:曲妥珠单抗与拉帕替尼联合用于乳腺癌新辅助治疗的随机对照研究的 Meta 分析
- Author:
Min CAO
;
Yunqiang WU
;
Ning LU
;
Jianguo HUANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoadjuvant therapy;
Meta-analysis;
Trastuzumab;
Lapatinib
- From:
Journal of International Oncology
2015;(4):269-273
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of trastuzumab versus the combination of tras-tuzumab and lapatinib added to neoadjuvant chemotherapy in HER2-positive breast cancer. Methods We searched PubMed,MEDLINE,The Cochrane Library,Web of Science,CNKI,Wanfang datebase and the abstracts of major international conferences in recent 5 years to identify randomized controlled trials which met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Hand-book. Meta-analysis was performed using RevMan 5. 0 software. Results Four trials were identified with 779 eli-gible patients. The results of meta-analyses showed that the rate of pathological complete response was significant-ly higher in the group receiving rastuzumab and tlapatinib than that in the group with trastuzumab alone(53. 3%vs 38. 8% ,RR =1. 39,95 % CI:1. 20-1. 63;P < 0. 001). No statistical differences were observed in regarding adverse events among patients receiving trastuzumab or the combination of trastuzumab and lapatinib,except the grade Ⅲ-Ⅳ diarrhea(2. 2% vs 25. 6% ,RR =11. 54,95% CI:5. 69-23. 41;P <0. 001). Conclusion The com-bination of trastuzumab and lapatinib added to neoadjuvant chemotherapy in HER2-positive breast cancer is more effective,without more adverse reactions except diarrhea;it ia an effective and safe treatment.
